Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

69.64 -1.65 (-2.31%)

Streaming Delayed Price Updated: 2:56 PM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	798,051
Open	70.94
Bid (Size)	69.60 (100)
Ask (Size)	69.69 (400)
Prev. Close	71.29
Today's Range	69.25 - 71.90
52wk Range	47.50 - 79.50
Shares Outstanding	142,334,900
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)

January 21, 2026

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its...

Via StockStory

Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

January 19, 2026

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals...

Via StockStory

Performance

YTD	-0.9%	-0.9%
1 Month	+1.9%	+1.9%
3 Month	+4.1%	+4.1%
6 Month	+18.5%	+18.5%
1 Year	+26.0%	+26.0%

More News

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗

January 19, 2026

Via The Motley Fool

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Via StockStory

Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen ↗

January 17, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

January 13, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗

January 06, 2026

Via Chartmill

1 Surging Stock Worth Investigating and 2 We Brush Off

January 11, 2026

Via StockStory

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

January 07, 2026

Via StockStory

Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks

January 04, 2026

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

January 01, 2026

Via StockStory

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

December 31, 2025

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Halozyme Therapeutics (NASDAQ:HALO): A Prime GARP Stock with Strong Growth and Value ↗

December 13, 2025

Via Chartmill

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. ↗

December 06, 2025

Via The Motley Fool

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗

November 24, 2025

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup ↗

November 21, 2025

Via Chartmill

Why I Keep Buying These 10 Incredible Growth Stocks ↗

November 17, 2025

Via The Motley Fool

Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Affordable Growth with Strong Metrics ↗

November 17, 2025

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum ↗

November 14, 2025

Via Chartmill

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Via Investor's Business Daily

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗

November 11, 2025

Via Chartmill

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗

November 05, 2025

Via The Motley Fool

Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Via The Motley Fool

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?

Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?

Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?

The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market

What is the current price of Halozyme Therapeutics, Inc. - Common Stock?

The current price of Halozyme Therapeutics, Inc. - Common Stock is 69.64

When was Halozyme Therapeutics, Inc. - Common Stock last traded?

The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 01/23/26 02:56 PM ET

What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?

The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 9.91B

How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?

Halozyme Therapeutics, Inc. - Common Stock has 10B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.